Showing papers by "Kalpana Joshi published in 2021"
TL;DR: The proposed approach of Ayurveda based phenotype screening may offer a way ahead to design customized strategies for management of COVID-19 based on differences in Prakriti, immune response and drug response, however, this needs clinical evaluation of the relation between Prakrati and genetic or phenotypic variants in CO VID-19 prone and resistant populations.
6 citations
TL;DR: In this article, the authors explored the activity of Piper longum L. fruit extract on proliferation and osteogenic differentiation of human Wharton's Jelly Mesenchymal Stem Cells (WJMSCs) to find out it's possible role as anti-osteoporotic agent.
5 citations
TL;DR: Two new flavonoids isolated from the methanol extract of Blumea eriantha DC have been isolated on the basis of spectroscopic techniques such as IR, MS, 1 D, and 2D NMR spectroscopy and showed significant but much lower reduction in cell viability as compared to the standard drug Paclitaxel.
3 citations
TL;DR: In this article, the efficacy and safety of polyherbal formulation (designated as IP) in comparison to placebo as add on to the standard of care (SoC) among patients with mild to moderate novel corona virus disease 2019 (COVID-19) were evaluated using quantitative reverse transcription-polymerase chain reaction (qRTPCR).
Abstract: ObjectiveTo assess the efficacy and safety of polyherbal formulation (designated as IP) in comparison to placebo as add on to the standard of care (SoC) among patients with mild to moderate novel corona virus disease 2019 (COVID-19) MethodsLaboratory proved patients of mild to moderate COVID-19 disease were randomized to either placebo or IP as an add-on to SoC. Using quantitative reverse transcription-polymerase chain reaction (qRTPCR), we assessed the effect on viral load (VL). Change in immunological parameters such as blood lymphocyte subset, serum immunoglobulin was determined. The clinical improvement was assessed using a numerical rating scale (NRS) and WHO ordinal scale. Patients were followed for 30 days after randomization. ResultsIn total, 72 patients were randomized to either placebo (n=33) and IP (n=39). Fifty-two patients (n=21 in placebo and n=31 in IP arm) had qRT-PCR on day 0 and day 4. There was significant reduction in VL in IP arm (from 662081 copies/mL on day 0 to 48963 copies/mL on day 4; p=0.002)) but not in the placebo arm (from 385670 copies/mL on day 0 to 66845 copies/mL on day 4, p=0.106). Change in the NRS score and WHO ordinal scale score was significant in both treatment arms. However, the difference between the two groups was statistically significant in favour of drug group. The increase in Th1 response was significant in the IP arm (p=0.023) but not in the placebo arm (p=0.098), thus implying immunomodulatory activity in the drug. No safety concerns were observed in any of the trial participants. ConclusionThis study finds that polyherbal formulation reduces viral load and contributes to immunomodulation and improvement in clinical conditions when used as add-on to the standard care in patients with mild to moderate COVID-19 without any side effects. These findings need to be further confirmed in a large, prospective, randomized study.
2 citations
TL;DR: DS can be explored as a novel inducer of IR in in vitro studies with further standardization, substituting the conventionally used pharmacological factors.
1 citations
TL;DR: In this paper, the authors discuss how human mesenchymal stem cells (hMSCs) can be used as an in vitro platform to screen herbs described in traditional medicine using modern methods such as evaluation of its potential, safety, quality, mode of action, etc.
Patent•
22 Mar 2021
TL;DR: In this article, a peroral or injectable pharmaceutical composition suitable for treatment of human immunodeficiency virus (HIV) usage, comprising a therapeutically effective amount of at least one antiretroviral drug, which contains reverse transcriptase inhibitor based on nucleotide analog (NRTI) selected from a group including: tenofovir alafenamide fumarate, tenofovalir disoproxil fumeter, adefovir and a combination thereof; or (ii) protease inhibitor (PI) containing darun
Abstract: FIELD: medicine.SUBSTANCE: invention relates to a peroral or injectable pharmaceutical composition suitable for treatment of human immunodeficiency virus (HIV) usage, comprising a therapeutically effective amount of at least one antiretroviral drug, which contains reverse transcriptase inhibitor based on nucleotide analog (NRTI) selected from a group including: tenofovir alafenamide fumarate, tenofovir disoproxil fumarate, adefovir and a combination thereof; or (ii) protease inhibitor (PI) containing darunavir and a therapeutically effective amount of at least one activator or pharmacokinetics improver which contains piperine, tetrahydropiperine, cis-piperine, trans-piperine, cis,trans-piperine, trans,cis-piperine, cis,cis-piperine, trans,trans-piperine, or a combination thereof. Present invention also relates to a producing method of a peroral or injectable pharmaceutical composition, to a treatment kit for human immunodeficiency virus (HIV), to the usage of a combination for increasing the bioavailability of an oral antiretroviral drug, to a peroral or injectable pharmaceutical composition suitable for hepatitis B viruses treatment, to a treatment kit for hepatitis B viruses.EFFECT: bioavailability of antiretroviral drugs enhancement.21 cl, 14 ex, 31 tbl, 8 dwg